Analyst Reco. Magenta Therapeutics

Equities

MGTA

US55910K1088

Real-time Estimate Cboe BZX Other stock markets 20:04:05 29/04/2024 BST			5-day change	1st Jan Change
21.82 ^USD	+1.49%		-7.53%	+96.54%

2023	Magenta Therapeutics, Inc.(NasdaqCM:MGTA) dropped from NASDAQ Composite Index	CI
2023	Dianthus Therapeutics, Inc. completed the acquisition of Magenta Therapeutics, Inc. from a group of shareholders in a reverse merger transaction.	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

HC Wainwright Initiates Magenta Therapeutics at Neutral	28/02/23	MT
BTIG Downgrades Magenta Therapeutics to Neutral From Buy	26/01/23	MT
Cowen Downgrades Magenta Therapeutics to Market Perform From Outperform	26/01/23	MT
Wedbush Downgrades Magenta Therapeutics to Neutral From Outperform on MGTA-117 Safety Issues, Lowers Price Targe to $1 From $3	26/01/23	MT
BTIG Lowers Price Target on Magenta Therapeutics to $3 From $6, Maintains Buy Rating	21/12/22	MT
Wedbush Adjusts Magenta Therapeutics Price Target to $3 From $6, Maintains Outperform Rating	20/12/22	MT
Goldman Sachs Downgrades Magenta Therapeutics to Neutral From Buy, Maintains $2 Price Target	25/08/22	MT
Goldman Sachs Adjusts Price Target for Magenta Therapeutics to $2 From $3, Keeps Buy Rating	24/05/22	MT
Wedbush Adjusts Magenta Therapeutics Price Target to $6 From $7, Maintains Outperform Rating	16/05/22	MT
Mizuho Securities Adjusts Magenta Therapeutics' Price Target to $8 From $17, Reiterates Buy Rating	18/04/22	MT
BTIG Adjusts Magenta Therapeutics' Price Target to $6 From $10, Reiterates Buy Rating	18/04/22	MT
Wedbush Adjusts Magenta Therapeutics Price Target to $7 From $9, Maintains Outperform Rating	14/04/22	MT
Wedbush Adjusts Magenta Therapeutics Price Target to $9 From $14, Maintains Outperform Rating	08/03/22	MT
B. Riley Lowers Magenta Therapeutics' Price Target to $6 from $13 After Revising Cost Capital Assumptions, Keeps Buy Rating	24/01/22	MT
Wedbush Trims Magenta Therapeutics' Price Target to $14 From $15, Keeps Outperform Rating	11/01/22	MT
Goldman Sachs Lifts Magenta Therapeutics to Buy From Neutral, Price Target to $8 From $7	06/01/22	MT
B. Riley Lowers Magenta Therapeutics' PT to $13 from $19 on Lower Peak Sales for MGTA-145, Keeps Buy Rating	08/11/21	MT
Wedbush Adjusts Price Target for Magenta Therapeutics to $15 From $20, Maintains Outperform Rating	04/11/21	MT
ANALYST RECOMMENDATIONS : Applied Industrials, Fastenal, Meggit, Planet Fitness, Krispy Kreme...	03/08/21
MAGENTA THERAPEUTICS : JPMorgan Cuts Magenta Therapeutics to Neutral From Overweight, Price Target to $7 From $16	03/08/21	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Magenta Therapeutics

Equities

MGTA

US55910K1088

Analyst Reco.

Filters